Avid Bioservices Inc (CDMO)

[freethemice]

Here are the numbers from the E4599 trial

Paclitaxel–Carboplatin (control group) N = 433
Male: 253 (58%)
Female: 180 (42%)

Median OS (combined): 10.3 months
Male: 8.7 months
Female: 13.1 months

Paclitaxel–Carboplatin–Bevacizumab (Avastin) N = 417
Male: 210 (50%)
Female: 207 (50%)

Median OS (combined): 12.3 months
Male: 11.7 months
Female: 13.3 months

Men had a 34% increase in their MOS, while women had a 1.5% increase!
So let's assume that Bavi + CP does as well for combined men and women, but men and women do equally well.
That is, they both have about a 33% increase in MOS. That to me is a selling point. If you can point to
data showing that Bavi overall works as well as Avastin, with less side effects, and that women can benefit from it too,
then I think you have an advantage.